AngioDynamics, Inc.

ANGO

US03475V1017

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
7.51 ^USD	+26.64%		+33.63%	-4.21%

16/07	Sector Update: Health Care Stocks Rise Late Afternoon	MT
16/07	Sector Update: Health Care Stocks Gain in Afternoon Trading	MT

AngioDynamics, Inc. Reaffirms Sales Guidance for the Fiscal Year 2021

January 07, 2021 at 05:30 pm IST

AngioDynamics, Inc. reaffirms Sales guidance for the fiscal year 2021. The company continues to expect fiscal year 2021 net sales in the range of $278 million to $284 million.

Latest news about AngioDynamics, Inc.

Sector Update: Health Care Stocks Rise Late Afternoon	17/07	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	16/07	MT
AngioDynamics Shares Rise After Fiscal Q4 Results, Share Repurchase Program	16/07	MT
Transcript : AngioDynamics, Inc., Q4 2024 Earnings Call, Jul 16, 2024	16/07
AngioDynamics, Inc. announces an Equity Buyback for $15 million worth of its shares.	16/07	CI
AngioDynamics, Inc. Reports Earnings Results for the Fourth Quarter Ended May 31, 2024	16/07	CI
AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2025	16/07	CI
Earnings Flash (ANGO) ANGIODYNAMICS Posts Q4 Revenue $71.1M, vs. Street Est of $70.9M	16/07	MT
Earnings Flash (ANGO) ANGIODYNAMICS Reports Q4 Loss $-0.05, vs. Street Est of $-0.17	16/07	MT
AngioDynamics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended May 31, 2024	16/07	CI
AngioDynamics, Inc. authorizes a Buyback Plan.	16/07	CI
AngioDynamics, Inc.(NasdaqGS:ANGO) dropped from Russell 2000 Defensive Index	01/07	CI
AngioDynamics, Inc.(NasdaqGS:ANGO) dropped from Russell 2000 Value-Defensive Index	01/07	CI
AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System	22/05	MT
AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)	07/05	CI
North American Morning Briefing : Inflation Data, -2-	08/04	DJ
Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target	05/04	MT
AngioDynamics Shares Jump After Fiscal Q3 Results, FDA Clearance For Device	04/04	MT
AngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 System	04/04	DJ
Transcript : AngioDynamics, Inc., Q3 2024 Earnings Call, Apr 04, 2024	04/04
AngioDynamics Gets FDA Clearance For Pulmonary Embolism Treatment	04/04	DJ
Earnings Flash (ANGO) ANGIODYNAMICS Reports Q3 Revenue $66M	04/04	MT
AngioDynamics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	04/04	CI
AngioDynamics, Inc. Reports Consolidated Goodwill Impairment for Third Quarter Ended February 29, 2024	04/04	CI
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024	04/04	CI

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

03/10/2024 - Q1 2025 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for AngioDynamics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.51 USD

Average target price

14.67 USD

Spread / Average Target

+95.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ANGIODYNAMICS, INC.	-4.21%	238M
ABBOTT LABORATORIES	-6.68%	179B
MEDTRONIC PLC	-5.20%	98.84B
BECTON, DICKINSON AND COMPANY	-5.38%	65.34B
HOYA CORPORATION	+18.04%	45.41B
DEXCOM, INC.	-6.47%	44.94B
CENCORA, INC.	+9.74%	43.76B
METTLER-TOLEDO INTERNATIONAL, INC.	+14.01%	29.01B
TERUMO CORPORATION	+21.55%	25.65B
WEST PHARMACEUTICAL SERVICES, INC.	-6.53%	23.32B

Other Medical Equipment, Supplies & Distribution